Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00183820 · ClinicalTrials.gov registry record · Phase 2
Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00183820 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 30 participants.
The verdict
NCT00183820, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a study for patients with advanced testicular cancer. This research study involves treatment with oxaliplatin, paclitaxel, and gemcitabine, which is an investigational chemotherapy combination. This study is for patients who have not responded to standard cisplatin-containing chemotherapy or the cancer has returned after such treatment. This research is being done to assess the effectiveness of the proposed combination of medications for this type of cancer.
Interventions
- DRUG paclitaxel, gemcitabine, and oxaliplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-11 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00183820
The ClinicalTrials.gov registry entry for NCT00183820 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which paclitaxel, gemcitabine, and oxaliplatin is the first listed.
NCT00183820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00183820 about?
NCT00183820 is a clinical study titled "Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma". This is a study for patients with advanced testicular cancer. This research study involves treatment with oxaliplatin, paclitaxel, and gemcitabine, which is an investigational chemotherapy combination. This study is for patients who have not responded to standard cisplatin-containing chemotherapy or...
What is the current status of trial NCT00183820?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2004-11. Estimated completion is 2016-08.
What interventions are being tested in trial NCT00183820?
The interventions under investigation include: paclitaxel, gemcitabine, and oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT00183820?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.